Bladder cancer breakthrough? immunotherapy and radiation join forces before surgery
NCT ID NCT05241340
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 34 times
Summary
This study tests a new approach for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. It combines an immunotherapy drug (sasanlimab) with targeted radiation to boost the immune system's ability to fight the tumor before surgical removal of the bladder. The goal is to see if this combination is safe and can lead to a complete disappearance of cancer in the removed bladder tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77006, United States
Conditions
Explore the condition pages connected to this study.